Current research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis

Acevedo, 2019, Redox active metals in neurodegenerative diseases, J. Biol. Inorg. Chem., 24, 1141, 10.1007/s00775-019-01731-9

Adlard, 2018, Metals and Alzheimer’s disease: how far have we come in the clinic?, J. Alzheimers Dis., 62, 1369, 10.3233/JAD-170662

Agliardi, 2019, SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer’s disease, Mol. Neurobiol., 56, 5792, 10.1007/s12035-019-1501-x

Ashton, 2019, Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration, Acta Neuropathol. Commun., 7, 5, 10.1186/s40478-018-0649-3

Ayton, 2021, Regional brain iron associated with deterioration in Alzheimer’s disease: a large cohort study and theoretical significance, Alzheimers Dement., 17, 1244, 10.1002/alz.12282

Badhwar, 2020, Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer’s disease, Alzheimers Dement., 12

Bai, 2013, Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer’s disease patients of Northern Han Chinese descent, Curr. Alzheimer Res., 10, 57

Barnard, 2014, Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease, Neurobiol. Aging, 35

Barthelemy, 2020, Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease, J. Exp. Med., 217

Bartoletti-Stella, 2018, Identification of rare genetic variants in Italian patients with dementia by targeted gene sequencing, Neurobiol. Aging, 66

Bauer, 2006, Classification of osteoarthritis biomarkers: a proposed approach, Osteoarthr. Cartil., 14, 723, 10.1016/j.joca.2006.04.001

Bayart, 2019, Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Abeta42 and T-Tau assays for Alzheimer’s disease diagnosis, J. Neurol., 266, 2304, 10.1007/s00415-019-09418-6

Beck, 2014, Validation of next-generation sequencing technologies in genetic diagnosis of dementia, Neurobiol. Aging, 35, 261, 10.1016/j.neurobiolaging.2013.07.017

Bernick, 2018, Longitudinal performance of plasma neurofilament light and tau in professional fighters: the professional fighters brain health study, J. Neurotrauma, 35, 2351, 10.1089/neu.2017.5553

Bird, 2008, Genetic aspects of Alzheimer disease, Genet. Med., 10, 231, 10.1097/GIM.0b013e31816b64dc

Bjerke, 2018, Cerebrospinal fluid biomarkers for early and differential Alzheimer’s disease diagnosis, J. Alzheimers Dis., 62, 1199, 10.3233/JAD-170680

Blennow, 2005, CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment, Expert Rev. Mol. Diagn., 5, 661, 10.1586/14737159.5.5.661

Blennow, 2003, CSF markers for incipient Alzheimer’s disease, Lancet Neurol., 2, 605, 10.1016/S1474-4422(03)00530-1

Bloom, 2014, Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis, JAMA Neurol., 71, 505, 10.1001/jamaneurol.2013.5847

Bonvicini, 2019, Next generation sequencing analysis in early onset dementia patients, J. Alzheimers Dis., 67, 243, 10.3233/JAD-180482

Brewer, 2010, Copper and ceruloplasmin abnormalities in Alzheimer’s disease, Am. J. Alzheimers Dis., 25, 490, 10.1177/1533317510375083

Casati, 2018, Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer’s disease, Eur. J. Neurol., 25, 805, 10.1111/ene.13583

Chen, 2018, Circulating APP, NCAM and Abeta serve as biomarkers for Alzheimer’s disease, Brain Res., 1699, 117, 10.1016/j.brainres.2018.08.015

Chhatwal, 2020, Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals, Nat. Commun., 11, 6024, 10.1038/s41467-020-19543-w

Chouraki, 2015, Plasma amyloid-beta and risk of Alzheimer’s disease in the Framingham Heart Study, Alzheimers Dement., 11

Chu, 2012, Alzheimer’s disease: early diagnosis and treatment, Hong Kong Med. J., 18, 228

Clarke, 2019, CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia, Alzheimers Res. Ther., 11, 105, 10.1186/s13195-019-0564-2

Collaborators, 2019, Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol., 18, 88, 10.1016/S1474-4422(18)30403-4

Copps, 2012, Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2, Diabetologia, 55, 2565, 10.1007/s00125-012-2644-8

Dage, 2016, Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort, Alzheimers Dement., 12, 1226, 10.1016/j.jalz.2016.06.001

Darst, 2018, Integrated analysis of genomics, longitudinal metabolomics, and Alzheimer’s risk factors among 1,111 cohort participants, Genet. Epidemiol., 43, 657, 10.1002/gepi.22211

Darst, 2021, Metabolites associated with early cognitive changes implicated in Alzheimer’s disease, J. Alzheimers Dis., 79, 1041, 10.3233/JAD-200176

Diouf, 2020, Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying beta-amyloid pathology, Neurobiol. Dis., 139, 10.1016/j.nbd.2020.104810

Du, 2017, Association of serum manganese levels with Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis, Nutrients, 9, 231, 10.3390/nu9030231

Ermert, 2003, In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue, Cytokine, 22, 89, 10.1016/S1043-4666(03)00117-0

Fandos, 2017, Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals, Alzheimers Dement., 8, 179

Faura, 2020, CCL23: a chemokine associated with progression from mild cognitive impairment to Alzheimer’s disease, J. Alzheimers Dis., 73, 1585, 10.3233/JAD-190753

Feng, 2018, Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease, BMC Neurol., 18, 4, 10.1186/s12883-017-1008-x

Ficiara, 2021, Alteration of iron concentration in Alzheimer’s disease as a possible diagnostic biomarker unveiling ferroptosis, Int. J. Mol. Sci., 22, 4479, 10.3390/ijms22094479

Fotuhi, 2019, Long non-coding RNA BACE1-AS may serve as an Alzheimer’s disease blood-based biomarker, J. Mol. Neurosci., 69, 351, 10.1007/s12031-019-01364-2

Ganguly, 2015, Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3, J. Phys. Chem. B, 119, 4582, 10.1021/acs.jpcb.5b00175

Goetzl, 2015, Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease, Neurology, 85, 40, 10.1212/WNL.0000000000001702

Goetzl, 2016, Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease, FASEB J., 30, 4141, 10.1096/fj.201600816R

Goldman, 2015, Genetic testing and counseling in the diagnosis and management of young-onset dementias, Psychiatr. Clin. North Am., 38, 295, 10.1016/j.psc.2015.01.008

Goldman, 2018, Alzheimer’s disease and frontotemporal dementia: the current state of genetics and genetic testing since the advent of next-generation sequencing, Mol. Diagn. Ther., 22, 505, 10.1007/s40291-018-0347-7

Goozee, 2018, Elevated plasma ferritin in elderly individuals with high neocortical amyloid-beta load, Mol. Psychiatry, 23, 1807, 10.1038/mp.2017.146

Gronewold, 2016, Factors responsible for plasma beta-amyloid accumulation in chronic kidney disease, Mol. Neurobiol., 53, 3136, 10.1007/s12035-015-9218-y

Guix, 2018, Detection of aggregation-competent tau in neuron-derived extracellular vesicles, Int. J. Mol. Sci., 19

Han, 2020, Genetic analysis of chinese patients with early-onset dementia using next-generation sequencing, Clin. Inter. Aging, 15, 1831, 10.2147/CIA.S271222

Han, 2012, Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer’s disease, Neurosci. Lett., 516, 232, 10.1016/j.neulet.2012.03.094

Hansson, 2018, CSF biomarkers of Alzheimer’s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts, Alzheimers Dement., 14, 1470, 10.1016/j.jalz.2018.01.010

Hardy, 1992, Alzheimer's disease: the amyloid cascade hypothesis, Science, 256, 184, 10.1126/science.1566067

Hare, 2016, Lead and manganese levels in serum and erythrocytes in Alzheimer’s disease and mild cognitive impairment: results from the Australian imaging, biomarkers and lifestyle flagship study of ageing, Metallomics, 8, 628, 10.1039/C6MT00019C

Hellman, 2002, Ceruloplasmin metabolism and function, Annu. Rev. Nutr., 22, 439, 10.1146/annurev.nutr.22.012502.114457

Hilal, 2018, Plasma amyloid-beta levels, cerebral atrophy and risk of dementia: a population-based study, Alzheimers Res. Ther., 10, 63, 10.1186/s13195-018-0395-6

Hornung, 2020, CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges, Front. Mol. Neurosci., 13, 38, 10.3389/fnmol.2020.00038

Hsu, 2017, Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer’s disease, Sci. Rep., 7, 5035, 10.1038/s41598-017-05390-1

Hu, 2019, Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults, Aging, 11, 6904, 10.18632/aging.102220

Hu, 2014, Increased expression of TREM2 in peripheral blood of Alzheimer’s disease patients, J. Alzheimers Dis., 38, 497, 10.3233/JAD-130854

Huang, 2012, beta-amyloid dynamics in human plasma, Arch. Neurol., 69, 1591, 10.1001/archneurol.2012.18107

Huo, Z., Yu, L., Yang, J., Zhu, Y., Bennett, D.A., Zhao, J., 2020. Corrigendum to brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis [Neurobiology of Aging Volume 86, February 2020, Pages 123–133]. Neurobiol Aging 91, 169.

Igarashi, 2015, Evaluation of dementia by acrolein, amyloid-beta and creatinine, Clin. Chim. Acta, 450, 56, 10.1016/j.cca.2015.07.017

Italiani, 2018, Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression?, J. Neuroinflamm., 15, 342, 10.1186/s12974-018-1376-1

Jack, 2018, NIA-AA research framework: toward a biological definition of Alzheimer’s disease, Alzheimers Dement, 14, 535, 10.1016/j.jalz.2018.02.018

Janelidze, 2016, Plasma beta-amyloid in Alzheimer’s disease and vascular disease, Sci. Rep., 6, 26801, 10.1038/srep26801

Janelidze, 2020, Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia, Nat. Med., 26, 379, 10.1038/s41591-020-0755-1

Janelidze, 2021, Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease, JAMA Neurol., 78, 149, 10.1001/jamaneurol.2020.4201

Jia, 2019, Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid, Alzheimers Dement., 15, 1071, 10.1016/j.jalz.2019.05.002

Jia, 2021, Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage, Alzheimers Dement., 17, 49, 10.1002/alz.12166

Jiang, 2011, Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease, Mol. Neurodegener., 6, 69, 10.1186/1750-1326-6-69

Jiang, 2019, Exosomes in pathogenesis, diagnosis, and treatment of Alzheimer’s disease, Med. Sci. Monit., 25, 3329, 10.12659/MSM.914027

Jiao, 2020, The validation of multifactor model of plasma abeta 42 and total-tau in combination with MoCA for diagnosing probable Alzheimer disease, Front. Aging Neurosci., 12, 212, 10.3389/fnagi.2020.00212

Kandimalla, 2016, Understanding aspects of aluminum exposure in Alzheimer’s disease development, Brain Pathol., 26, 139, 10.1111/bpa.12333

Kaneko, 2014, Novel plasma biomarker surrogating cerebral amyloid deposition, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 90, 353, 10.2183/pjab.90.353

Kaplow, 2020, Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status, Alzheimers Dement., 16, 144, 10.1002/alz.12000

Kapogiannis, 2015, Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease, FASEB J., 29, 589, 10.1096/fj.14-262048

Karikari, 2020, Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts, Lancet Neurol., 19, 422, 10.1016/S1474-4422(20)30071-5

Karikari, 2021, Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative, Mol. Psychiatry, 429, 10.1038/s41380-020-00923-z

Karim, 2019, Apolipoprotein E4 genotype in combination with poor metabolic profile is associated with reduced cognitive performance in healthy postmenopausal women: implications for late onset Alzheimer's disease, Menopause, 26, 7, 10.1097/GME.0000000000001160

Karsdal, 2009, Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development, Biomarkers, 14, 181, 10.1080/13547500902777608

Kawahara, 2011, Link between aluminum and the pathogenesis of Alzheimer’s disease: the integration of the aluminum and amyloid cascade hypotheses, Int. J. Alzheimers Dis., 2011

Kellar, 2020, Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches, Lancet Neurol., 19, 758, 10.1016/S1474-4422(20)30231-3

Kester, 2011, Decreased mRNA expression of CCL5 [RANTES] in Alzheimer’s disease blood samples, Clin. Chem. Lab. Med., 50, 61

Klatzo, 1965, Experimental production of neurofibrillary degeneration. I. Light microscopic observations, J. Neuropathol. Exp. Neurol., 24, 187, 10.1097/00005072-196504000-00002

Koychev, 2021, Blood-based ATN biomarkers of Alzheimer’s disease: a meta-analysis, J. Alzheimers Dis., 79, 177, 10.3233/JAD-200900

Krishna, 2020, Higher levels of lysosomal associated membrane protein-2 (LAMP-2) in plasma exosomes from Alzheimer’s disease: an exploratory study from South India, Asian J. Psychiatr., 48, 10.1016/j.ajp.2019.101898

Kulczynska-Przybik, 2020, Cerebrospinal fluid and blood CX3CL1 as a potential biomarker in early diagnosis and prognosis of dementia, Curr. Alzheimer Res., 17, 709, 10.2174/1567205017666201109095657

Kumar, 2016, Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease?, Biochim. Biophys. Acta, 1862, 1617, 10.1016/j.bbadis.2016.06.001

Lachno, 2011, Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer’s disease studies, J. Alzheimers Dis., 26, 531, 10.3233/JAD-2011-110296

Lachno, 2012, Validation of a multiplex assay for simultaneous quantification of amyloid-beta peptide species in human plasma with utility for measurements in studies of Alzheimer’s disease therapeutics, J. Alzheimers Dis., 32, 905, 10.3233/JAD-2012-121075

Lachno, 2015, Validation and clinical utility of ELISA methods for quantification of amyloid-beta of peptides in cerebrospinal fluid specimens from Alzheimer’s disease studies, J. Alzheimers Dis., 45, 527, 10.3233/JAD-141686

Leitao, 2019, Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease, Alzheimers Res. Ther., 11, 91, 10.1186/s13195-019-0550-8

Leuzy, 2019, Tau PET imaging in neurodegenerative tauopathies-still a challenge, Mol. Psychiatry, 24, 1112, 10.1038/s41380-018-0342-8

Li, 2017, Serum copper, zinc, and iron levels in patients with Alzheimer’s disease: a meta-analysis of case-control studies, Front. Aging Neurosci., 9, 300, 10.3389/fnagi.2017.00300

Li, 2019, Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease, Mech. Ageing Dev., 184, 10.1016/j.mad.2019.111175

Lidsky, 2014, Is the Aluminum Hypothesis dead?, J Occup Environ Med, 56, S73, 10.1097/JOM.0000000000000063

Lifke, 2019, Elecsys((R)) Total-Tau and Phospho-Tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid, Clin. Biochem., 72, 30, 10.1016/j.clinbiochem.2019.05.005

Lim, 2018, Association of beta-amyloid and apolipoprotein E epsilon4 with memory decline in preclinical Alzheimer disease, JAMA Neurol., 75, 488, 10.1001/jamaneurol.2017.4325

Lopez, 2019, Blood amyloid levels and risk of dementia in the ginkgo evaluation of memory study (GEMS): a longitudinal analysis, Alzheimers Dement., 15, 1029, 10.1016/j.jalz.2019.04.008

Lugli, 2015, Plasma exosomal miRNAs in persons with and without alzheimer disease: altered expression and prospects for biomarkers, PLoS One, 10, 10.1371/journal.pone.0139233

Mattsson, 2013, CSF biomarker variability in the Alzheimer’s association quality control program, Alzheimers Dement., 251, 10.1016/j.jalz.2013.01.010

Mattsson, 2016, Plasma tau in Alzheimer disease, Neurology, 1827, 10.1212/WNL.0000000000003246

Mattsson, 2017, Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease, JAMA Neurol., 74, 557, 10.1001/jamaneurol.2016.6117

Mattsson, 2019, Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease, JAMA Neurol., 76, 791, 10.1001/jamaneurol.2019.0765

McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement., 7, 263, 10.1016/j.jalz.2011.03.005

Mehta, 2000, Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease, Arch. Neurol., 57, 100, 10.1001/archneur.57.1.100

Meng, 2019, Association between increased levels of amyloid-beta oligomers in plasma and episodic memory loss in Alzheimer’s disease, Alzheimers Res. Ther., 11, 89, 10.1186/s13195-019-0535-7

Mietelska-Porowska, 2017, T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer’s disease: potential pools of new biomarkers, J. Immunol. Res., 2017, 10.1155/2017/4626540

Montalbano, 2020, TDP-43 and tau oligomers in Alzheimer’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia, Neurobiol. Dis., 146, 10.1016/j.nbd.2020.105130

Moscoso, 2021, Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease, JAMA Neurol., 78, 396, 10.1001/jamaneurol.2020.4986

Moscoso, 2021, Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum, Brain, 144, 325, 10.1093/brain/awaa399

Mullins, 2017, Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease, Front. Aging Neurosci., 9, 118, 10.3389/fnagi.2017.00118

Mullins, 2017, Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease, Hum. Brain Mapp., 38, 1933, 10.1002/hbm.23494

Nakamura, 2018, High performance plasma amyloid-beta biomarkers for Alzheimer's disease, Nature, 554, 249, 10.1038/nature25456

Nixon, 2017, Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease, FASEB J., 31, 2729, 10.1096/fj.201700359

O’Bryant, 2015, Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research, Alzheimers Dement., 11, 549, 10.1016/j.jalz.2014.08.099

Palmqvist, 2019, Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status, JAMA Neurol., 76, 1060, 10.1001/jamaneurol.2019.1632

Palmqvist, 2020, Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders, JAMA, 324, 772, 10.1001/jama.2020.12134

Park, 2017, Chemically treated plasma Abeta is a potential blood-based biomarker for screening cerebral amyloid deposition, Alzheimers Res. Ther., 9, 20, 10.1186/s13195-017-0248-8

Park, 2014, Elevated serum copper and ceruloplasmin levels in Alzheimer’s disease, Asia Pac. Psychiatry, 6, 38, 10.1111/appy.12077

Pase, 2019, Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes, JAMA Neurol., 76, 598, 10.1001/jamaneurol.2018.4666

Perez-Grijalba, 2019, Plasma Abeta42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study, Alzheimers Res. Ther., 11, 96, 10.1186/s13195-019-0549-1

Polanco, 2018, Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies, Nat. Rev. Neurol., 14, 22, 10.1038/nrneurol.2017.162

Rabinovici, 2019, Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia, JAMA, 321, 1286, 10.1001/jama.2019.2000

Raket, 2020, Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer’s disease, Alzheimers Dement., 12

Rodriguez, 2020, Plasma p‐tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post‐mortem and improves the clinical characterisation of cognitive decline, Alzheimers Dement., 16, 267, 10.1002/alz.047539

Sardar Sinha, 2018, Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers, Acta Neuropathol., 136, 41, 10.1007/s00401-018-1868-1

Sastre, 2006, Contribution of inflammatory processes to Alzheimer’s disease: molecular mechanisms, Int. J. Dev. Neurosci., 24, 167, 10.1016/j.ijdevneu.2005.11.014

Selkoe, 2004, Alzheimer disease: mechanistic understanding predicts novel therapies, Ann. Intern. Med., 140, 627, 10.7326/0003-4819-140-8-200404200-00047

Sensi, 2018, Copper and zinc dysregulation in Alzheimer’s disease, Trends Pharm. Sci., 39, 1049, 10.1016/j.tips.2018.10.001

Shahpasand-Kroner, 2018, A two-step immunoassay for the simultaneous assessment of Abeta38, Abeta40 and Abeta42 in human blood plasma supports the Abeta42/Abeta40 ratio as a promising biomarker candidate of Alzheimer’s disease, Alzheimers Res. Ther., 10, 121, 10.1186/s13195-018-0448-x

Shih, 2020, TDP-43 interacts with amyloid-beta, inhibits fibrillization, and worsens pathology in a model of Alzheimer’s disease, Nat. Commun., 11, 5950, 10.1038/s41467-020-19786-7

Siotto, 2016, Association between serum ceruloplasmin specific activity and risk of Alzheimer’s disease, J. Alzheimers Dis., 50, 1181, 10.3233/JAD-150611

Soria Lopez, 2019, Alzheimer’s disease, Handb. Clin. Neurol., 167, 231, 10.1016/B978-0-12-804766-8.00013-3

Spitzer, 2019, Analysis of surface levels of IL-1 receptors and macrophage scavenger receptor I in peripheral immune cells of patients with Alzheimer disease, J. Geriatr. Psychiatry Neurol., 32, 211, 10.1177/0891988719841728

Squitti, 2009, Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease, Neurology, 72, 50, 10.1212/01.wnl.0000338568.28960.3f

Squitti, 2014, Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease, Ann. Neurol., 75, 574, 10.1002/ana.24136

Squitti, 2017, Measurements of serum non-ceruloplasmin copper by a direct fluorescent method specific to Cu(II), Clin. Chem. Lab. Med, 55, 1360, 10.1515/cclm-2016-0843

Squitti, 2021, Copper Imbalance in Alzheimer’s Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology, J. Alzheimers Dis., 10.3233/JAD-201556

Squitti, 2021, Copper imbalance in Alzheimer’s disease: meta-analysis of serum, plasma, and brain specimens, and replication study evaluating ATP7B gene variants, Biomolecules, 11, 960, 10.3390/biom11070960

Stocker, 2020, Prediction of Alzheimer’s disease diagnosis within 14 years through Abeta misfolding in blood plasma compared to APOE4 status, and other risk factors, Alzheimers Dement., 16, 283, 10.1016/j.jalz.2019.08.189

Streit, 2004, Microglia and neuroinflammation: a pathological perspective, J. Neuroinflamm., 1, 14, 10.1186/1742-2094-1-14

Strobel, 2015, Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARgamma, J. Neural Transm., 122, 1069, 10.1007/s00702-015-1369-5

Sugarman, 2020, A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer’s disease, Neurobiol. Aging, 94, 60, 10.1016/j.neurobiolaging.2020.05.011

Sun, 2014, Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer’s disease, J. Alzheimers Dis., 41, 877, 10.3233/JAD-140177

Sun, 2020, Plasma neurofilament light and longitudinal progression of white matter hyperintensity in elderly persons without dementia, J. Alzheimers Dis., 75, 729, 10.3233/JAD-200022

Talbot, 2014, The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease, Alzheimers Dement, 10, S12, 10.1016/j.jalz.2013.12.007

Tan, 2014, Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer’s disease, J. Alzheimers Dis., 40, 1017, 10.3233/JAD-132144

Tan, 2017, Higher peripheral TREM2 mRNA levels relate to cognitive deficits and hippocampal atrophy in Alzheimer’s disease and amnestic mild cognitive impairment, J. Alzheimers Dis., 58, 413, 10.3233/JAD-161277

Thijssen, 2020, Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration, Nat. Med., 26, 387, 10.1038/s41591-020-0762-2

Tonnies, 2017, Oxidative stress, synaptic dysfunction, and Alzheimer’s disease, J. Alzheimers Dis., 57, 1105, 10.3233/JAD-161088

Toral-Rios, 2020, GSK3beta and tau protein in Alzheimer’s disease and epilepsy, Front. Cell. Neurosci., 14, 19, 10.3389/fncel.2020.00019

van Oijen, 2006, Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study, Lancet Neurol., 5, 655, 10.1016/S1474-4422(06)70501-4

Varma, 2018, Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study, PLoS Med., 15, 10.1371/journal.pmed.1002482

Ventriglia, 2015, Zinc in Alzheimer’s disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies, J. Alzheimers Dis., 46, 75, 10.3233/JAD-141296

Verberk, 2020, Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology, Alzheimers Res. Ther., 12, 118, 10.1186/s13195-020-00682-7

Verite, 2018, Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice, J. Neuroinflamm., 15, 182, 10.1186/s12974-018-1220-7

Vérité J, 2018, Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model, PLoS One, 13, 10.1371/journal.pone.0201232

Virk, 2015, Aluminum levels in brain, serum, and cerebrospinal fluid are higher in Alzheimer’s disease cases than in controls: a series of meta-analyses, J. Alzheimers Dis., 47, 629, 10.3233/JAD-150193

Vishal, 2011, Alois Alzheimer (1864-1915) and the Alzheimer syndrome, J. Med. Biogr., 19, 32, 10.1258/jmb.2010.010037

Wang, 2020, Elevated plasma levels of exosomal BACE1AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer’s disease, Mol. Med. Rep., 22, 227, 10.3892/mmr.2020.11118

Wang, 2012, Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer’s disease, J. Alzheimers Dis., 31, 439, 10.3233/JAD-2012-120082

Wang, 2019, TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response, PLoS Genet., 15, 10.1371/journal.pgen.1007947

Wang, 2017, Associations between hepatic functions and plasma amyloid-beta levels-implications for the capacity of liver in peripheral amyloid-beta clearance, Mol. Neurobiol., 54, 2338, 10.1007/s12035-016-9826-1

Wang, 2015, Serum iron, zinc, and copper levels in patients with alzheimer’s disease: a replication study and meta-analyses, J. Alzheimers Dis., 47, 565, 10.3233/JAD-143108

Wei, 1992, Increase of plasma IL-6 concentration with age in healthy subjects, Life Sci., 51, 1953, 10.1016/0024-3205(92)90112-3

Wilczynska, 2020, Diagnostic utility of selected serum dementia biomarkers: amyloid beta-40, amyloid beta-42, tau protein, and YKL-40: a review, J. Clin. Med., 9

de Wolf, 2020, Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study, Brain, 143, 1220, 10.1093/brain/awaa054

Wong, 2013, Challenges of bringing next generation sequencing technologies to clinical molecular diagnostic laboratories, Neurotherapeutics, 10, 262, 10.1007/s13311-012-0170-5

Wu, 2016, Circulating microRNAs as biomarkers of Alzheimer’s disease: a systematic review, J. Alzheimers Dis., 49, 755, 10.3233/JAD-150619

Wu, 2015, Alterations of the neuroinflammatory markers IL-6 and TRAIL in Alzheimer’s disease, Dement Geriatr. Cogn. Dis. Extra, 5, 424, 10.1159/000439214

Yang, 2018, The serum exosome derived microRNA-135a, -193b, and -384 were potential Alzheimer’s disease biomarkers, Biomed. Environ. Sci., 31, 87

Youn, 2019, Blood amyloid-beta oligomerization associated with neurodegeneration of Alzheimer’s disease, Alzheimers Res. Ther., 11, 40, 10.1186/s13195-019-0499-7

Youn, 2020, Blood Amyloid-beta oligomerization as a biomarker of Alzheimer’s disease: a blinded validation study, J. Alzheimers Dis., 75, 493, 10.3233/JAD-200061

Zhang, 2018, Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease, Alzheimers Res. Ther., 10, 80, 10.1186/s13195-018-0407-6

Zhang, 2013, Combination of plasma tumor necrosis factor receptors signaling proteins, beta-amyloid and apolipoprotein E for the detection of Alzheimer’s disease, Neurosci. Lett., 541, 99, 10.1016/j.neulet.2013.03.007

Zhang, 2014, Plasma amyloid-beta oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD, Curr. Alzheimer Res., 11, 325, 10.2174/1567205011666140317103222

Zhang, 2020, TDP-43 is elevated in plasma neuronal-derived exosomes of patients with Alzheimer’s disease, Front. Aging Neurosci., 12, 166, 10.3389/fnagi.2020.00166

Zhang, 2020, Novel tau filament fold in corticobasal degeneration, Nature, 580, 283, 10.1038/s41586-020-2043-0